Levosert (Levonorgestrel)

Levonorgestrel released from Levosert at about 20 µg per day acts locally to thicken cervical mucus, making it difficult for sperm to enter the uterus. It also impairs sperm motility and viability, suppresses growth of the endometrial lining, and may occasionally inhibit ovulation, together preventing fertilisation and implantation.

The dose is fixed within the device; each Levosert contains 52 mg of levonorgestrel that releases roughly 20 µg per day. The prescribing clinician determines whether the device is appropriate for a patient and decides the timing of insertion. No patient‑adjusted dosing or daily administration is required.

Levosert is contraindicated in pregnancy (Category X) and must not be inserted in a pregnant woman. If pregnancy occurs while the device is in place, it should be removed promptly. Limited data exist for breastfeeding; clinicians typically advise caution and may consider alternative contraceptive methods for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levosert releases levonorgestrel, which can reduce menstrual bleeding and cause fewer cramping episodes compared with copper IUDs that often increase bleeding. Both provide high efficacy for up to five years, but the hormonal IUS offers additional benefits such as lighter periods, whereas copper devices are non‑hormonal and suitable for women who prefer a hormone‑free option.

Levosert should be stored at room temperature, below 25 °C, in its original sealed packaging. The device must be protected from moisture, extreme heat and direct sunlight to maintain the integrity of the levonorgestrel reservoir until insertion.

Levosert is a T‑shaped intrauterine system inserted by a trained healthcare professional through the cervical canal into the uterine cavity. Insertion is performed in a clinical setting using a sterile inserter, and the device remains in place for up to five years without any daily user action.

Serious but rare risks include uterine perforation during insertion, expulsion of the device, pelvic infection such as pelvic inflammatory disease, and the possibility of ectopic pregnancy if contraception fails. Prompt medical evaluation is required if severe abdominal pain, abnormal bleeding or signs of infection occur.

Levosert is contraindicated in women who are currently pregnant, have active pelvic infections, known hypersensitivity to levonorgestrel, uterine anomalies that preclude device placement, or a history of breast cancer. It should also be avoided in individuals with unexplained vaginal bleeding until the underlying cause is identified.